Year Founded
2004
Ownership
Public
Employees
~50
Therapeutic Areas
Oncology
Stage
Phase 2
Modalities
Gene therapy

Anchiano Therapeutics General Information

Lead product inodiftagene showed 33% complete response rate in Phase 2 NMIBC trial. Phase 2 Codex trial ongoing in BCG-unresponsive NMIBC patients. Phase 3 Leo trial planned in BCG-failure patients.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Jerusalem,
Israel

Drug Pipeline

inodiftagene
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Anchiano Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Anchiano Therapeutics Funding

Deal TypeDateAmountStatusStage
Later Stage VCApr 13, 2018$23.0MCompletedPhase 2
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Anchiano Therapeutics's complete valuation and funding history, request access »

Anchiano Therapeutics Investors

Arc Ventures,[3]
Investor Type: Venture Capital
Holding: Minority
public market investors via IPO/Nasdaq listing
Investor Type: Venture Capital
Holding: Minority